By David Wallace – Patient perspective | September 25, 2026
The established polycythemia vera hematocrit target is below 45%. That goal lowers the risk of serious blood clots and cardiovascular death. It does not necessarily mean symptom relief.
I learned that the hard way. My circulation-related symptoms often started around 42%, well before I hit the usual phlebotomy trigger near 45%. For some patients with persistent symptoms like that, expert recommendations support considering a lower individual target with their hematologist.
Before changing the target, look at what else may be contributing. PV-related inflammation, iron deficiency, treatment effects, sleep problems, and other health conditions can cause overlapping symptoms. Fatigue or brain fog alone cannot tell you whether your hematocrit needs to be lower.
Key Takeaways
- Below 45% remains the established general target for PV.
- Persistent circulation-related symptoms may justify a personal target if the benefit outweighs the burden.
- Symptom assessment, iron status, and treatment burden belong alongside blood counts in your care plan.
Why the Polycythemia Vera Hematocrit Target Is Below 45%
Hematocrit, often shortened to Hct, measures the percentage of blood volume occupied by red blood cells. PV causes excess red blood cell production, which can increase blood viscosity, or thickness.
The landmark CYTO-PV trial randomly assigned 365 patients to a target below 45% or between 45% and 50%. After a median of 31 months, cardiovascular death or a major clot occurred in 2.7% of the lower-target group versus 9.8% of the higher-target group.
That trial established the benefit of keeping hematocrit below 45%. It did not test whether routinely aiming lower within that range provides additional protection against clots.
When Persistent Symptoms May Call for an Individualized Hematocrit Target
Barbui and colleagues’ 2018 phlebotomy recommendations, as summarized in a 2024 peer-reviewed review, support a lower individual target for persistent or recurrent symptoms of hyperviscosity despite the standard target. Examples include headaches, dizziness, visual disturbances, and erythromelalgia, meaning burning pain and redness in the hands or feet. Documented symptom improvement should guide this approach.
The 2025 Italian Delphi consensus by Bonifacio and colleagues makes this point explicitly. Its treatment recommendations support considering 40–42% for patients with persistent symptoms of microcirculatory disturbance despite otherwise controlled hematocrit, if the lower target is tolerated. Microcirculatory disturbance means problems with blood flow through small vessels. This recommendation reflects expert agreement reached through a structured voting process.
These expert recommendations support a lower goal for selected symptomatic patients. They do not establish that everyone benefits from a lower target. Discuss whether your symptoms fit this pattern with your healthcare team.
Why Controlled Counts May Not Mean Controlled Symptoms
In the REVEAL study analysis, symptom burden persisted despite blood count control. This supports assessing how patients feel separately from laboratory results.
Scherber and colleagues also examined symptoms using CYTO-PV and MPN-SAF patient data. Their analysis did not show a consistent symptom advantage from stricter hematocrit control. Together, these findings explain why a symptom evaluation should look beyond one number.
When to seek emergency care
Seek emergency care for sudden or severe chest pain, shortness of breath, vision loss, or stroke symptoms. New or worsening symptoms need prompt assessment. Do not wait for another blood count or assume hematocrit explains them.
Why 42% Is My Personal Action Threshold
My symptoms consistently began at a hematocrit of 42% or above. At 42.9%, or 43.5%, I already had some degree of chest pain and shortness of breath. Even at 44.5% or 44.8%, I was told to return in a week or two to see whether I had reached 45% for phlebotomy. I lived with those symptoms while I waited.
Before I found my current doctor, those symptoms had been attributed to PV. At our first visit, he listened and agreed to a goal below 42%, with phlebotomy at 42% or higher. He also referred me to a cardiologist and pulmonologist. Neither found a heart or lung condition that explained what I was feeling. Keeping my hematocrit lower has helped relieve the symptoms.
This is my experience, not a target I recommend for anyone else. How we feel still belongs next to our blood counts.
The Tradeoff With Phlebotomy and Iron Deficiency
A lower target may mean more phlebotomies. Each treatment removes red blood cells and iron. Repeated blood removal can deepen iron deficiency, contributing to fatigue, weakness, or difficulty concentrating, even without anemia.
Your hematologist can weigh symptom relief against treatment burden by reviewing iron tests, blood counts, and your response.
Medication changes may also be appropriate. Avoid starting iron supplements without medical guidance because added iron can increase red blood cell production.
The August 2026 FDA approval of MIMRYLO (rusfertide) adds another option for hematocrit control in adults with PV. It mimics hepcidin, a hormone that regulates iron availability, helping limit excess red blood cell production and reduce the need for phlebotomy. Its pivotal trial targeted hematocrit below 45%. Whether it fits your treatment plan is a discussion to have with your healthcare team.
How to Track Hematocrit and Symptoms
A short record can help your doctor assess whether there is a repeatable pattern.
- Record the date, hematocrit, and other available blood counts.
- Rate recurring symptoms from 0 to 10 and note their effect on daily activities.
- Log phlebotomies, medication changes, and whether any improvement lasts.
- Note poor sleep, illness, or other factors that may affect how you feel.
Bring the record to your appointment with your questions about PV care. Ask which symptoms might respond to tighter control, how benefit would be measured, and what would prompt a treatment change. If concerns remain unresolved, an MPN specialist can offer another perspective.
Common Questions About PV Hematocrit
Should everyone aim lower than the standard target?
No. A lower individual target is an option for selected patients with persistent circulation-related symptoms. Below 45% remains the general target.
What if phlebotomy provides little or only brief relief?
Tell your hematologist. That pattern may prompt reassessment of iron deficiency, other symptom causes, and the overall treatment plan instead of simply repeating blood removal.
Keeping hematocrit below 45% remains central to PV care. Persistent symptoms still deserve a closer look.
References
- Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular Events and Intensity of Treatment in Polycythemia Vera. New England Journal of Medicine. 2013;368:22–33.
- Barbui T, Passamonti F, Accorsi P, et al. Evidence- and consensus-based recommendations for phlebotomy in polycythemia vera. Leukemia. 2018;32(9):2077–2081.
- Bonifacio M, Breccia M, Guglielmelli P, et al. Recommendations for best management of polycythemia vera in Italy: a Delphi consensus statement. Leukemia & Lymphoma. 2025;66(11):2017–2025. Published online July 2, 2025.
- Visweshwar N, et al. Impact of Phlebotomy on Quality of Life in Low-Risk Polycythemia Vera. Journal of Clinical Medicine. 2024;13(16):4952.
- Grunwald MR, Burke JM, Kuter DJ, et al. Symptom Burden and Blood Counts in Patients With Polycythemia Vera in the United States: An Analysis From the REVEAL Study. Clinical Lymphoma, Myeloma & Leukemia. 2019;19(9):579–584.e1.
- Scherber RM, Geyer HL, Dueck AC, et al. The potential role of hematocrit control on symptom burden among polycythemia vera patients: Insights from the CYTO-PV and MPN-SAF patient cohorts. Leukemia & Lymphoma. 2017;58(6):1481–1487.
- Ginzburg YZ, Feola M, Zimran E, et al. Dysregulated iron metabolism in polycythemia vera: etiology and consequences. Leukemia. 2018;32:2105–2116.
- U.S. Food and Drug Administration. FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood Disorder. August 28, 2026.
About the Author
David Wallace is a nationally recognized myeloproliferative neoplasm (MPN) patient advocate, writer, and the founder and publisher of PV Reporter. He also founded MPN Cancer Connection, a 501(c)(3) nonprofit organization, and serves as its executive director. Diagnosed with polycythemia vera in 2009 and now in complete molecular remission, David has spent more than a decade helping patients understand MPN research, treatment options, and the questions to ask their healthcare teams. His work brings the patient voice into discussions with clinicians, researchers, and industry leaders.
Medical Disclaimer
This article is for educational purposes only and is not medical advice. It does not replace consultation with a qualified hematologist or MPN specialist. Discuss all diagnosis and treatment decisions with your healthcare team.
